Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
Lyndsay Harris,Gerald Batist,Robert Belt,Douglas Rovira,Rudolph Navari,Nozar Azarnia,Lauri Welles,Eric Winer,Eric Winer +8 more
Reads0
Chats0
TLDR
The objective of this study was to compare the efficacy and toxicity of the liposome‐encapsulated doxorubicin, TLC D‐99 (Myocet, Elan Pharmaceuticals, Princeton, NJ), and conventional doxorbicin in first‐line treatment of metastatic breast carcinoma (MBC).Abstract:
BACKGROUND
The objective of this study was to compare the efficacy and toxicity of the liposome-encapsulated doxorubicin, TLC D-99 (Myocet, Elan Pharmaceuticals, Princeton, NJ), and conventional doxorubicin in first-line treatment of metastatic breast carcinoma (MBC).
METHODS
Two hundred twenty-four patients with MBC and no prior therapy for metastatic disease were randomized to receive either TLC D-99 (75 mg/m2) or doxorubicin (75 mg/m2) every 3 weeks, in the absence of disease progression or unacceptable toxicity. The primary efficacy endpoint was response rate. Responses were assessed using World Health Organization criteria and were required to be of at least 6 weeks' duration. The primary safety endpoint was cardiotoxicity. Cardiac function was monitored by multiple-gated radionuclide cardioangiography scan, and the left ventricular ejection fraction (LVEF) was scored at a central laboratory. Patients were removed from study if LVEF declined 20 or more EF units from baseline to a final value of greater than or equal to 50%, or by 10 or more units to a final value of less than 50%, or onset of clinical congestive heart failure (CHF).
RESULTS
Median age was 54 years in both treatment groups. All relevant prog nostic factors were balanced, with the exception that there were significantly more progesterone receptor positive patients in the doxorubicin-treated group. Protocol-defined cardiotoxicity was observed in 13% of TLC D-99 patients (including 2 cases of CHF) compared to 29% of doxorubicin patients (including 9 cases of CHF). Median cumulative doxorubicin dose at onset of cardiotoxicity was 785 mg/m2 for TLC D-99 versus 570 mg/m2 for doxorubicin (P = 0.0001; hazard ratio, 3.56). The overall response rate was 26% in both treatment groups. The median TTP was 2.9 months on TLC D-99 versus 3.1 months on doxorubicin. Median survival was 16 versus 20 months with a nonsignificant trend in favor of doxorubicin (P = 0.09). Clinical toxicities, commonly associated with doxorubicin, appeared less common with TLC D-99, although the difference was not statistically significant. There was only one report of palmar-plantar erythrodysesthesia (Grade 2) with this liposomal formulation of doxorubicin.
CONCLUSIONS
Single-agent TLC D-99 produces less cardiotoxicity than doxorubicin, while providing comparable antitumor activity. Cancer 2002;94:25–36. © 2002 American Cancer Society.read more
Citations
More filters
Journal ArticleDOI
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter +15 more
TL;DR: This document describes the development and use of angiotensin-converting enzyme, a non-volatile substance that acts as a “spatially aggregating substance” to reduce the chances of heart attack in women.
Journal ArticleDOI
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
Mary O'Brien,Nely Wigler,Moshe Inbar,R. Rosso,E. Grischke,Armando Santoro,Raphael Catane,D. G. Kieback,Piotr Tomczak,Stephen P. Ackland,F. Orlandi,L. Mellars,L. Alland,C. Tendler +13 more
TL;DR: In first-line therapy for MBC, PLD provides comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity, myelosuppression, vomiting and alopecia.
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter,Stephan Achenbach,Stefan Agewall,Lina Badimon,Gonzalo Barón-Esquivias,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Scipione Carerj,Veronica Dean,Çetin Erol,Donna Fitzsimons,Oliver Gaemperli,Paulus Kirchhof,Philippe Kolh,Petros Nihoyannopoulos,Piotr Ponikowski,Marco Roffi,Antonio Vaz Carneiro,Stephan Windecker +34 more
TL;DR: No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.
Journal ArticleDOI
Nanoparticle Delivery of Cancer Drugs
TL;DR: The various nanoparticles drug delivery platforms and the important concepts involved in nanoparticle drug delivery are discussed and the clinical data on the approved nanoparticle therapeutics as well as the nanotherapeutics under clinical investigation are reviewed.
References
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Risk factors for doxorubicin-induced congestive heart failure.
TL;DR: There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
Journal ArticleDOI
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Stephen Chan,K. Friedrichs,Daniel Noel,Tamás Pintér,Simon Van Belle,Daniel A. Vorobiof,Ricardo Duarte,M. Gil,Istvan Bodrogi,Elizabeth Murray,Louise Yelle,Gunter von Minckwitz,Stefan Korec,Peter Simmonds,Franco Buzzi,Rosario González Mancha,Gary Richardson,Euan Walpole,Monica Ronzoni,Michael Murawsky,May Alakl,Alessandro Riva,John Crown +22 more
TL;DR: The observed differences in activity and toxicity profiles provide a basis for therapy choice and confirms the rationale for combination studies in early breast cancer.
Journal ArticleDOI
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
Soonmyung Paik,John Bryant,Chanheun Park,Bernard Fisher,Elizabeth Tan-Chiu,David Hyams,Edwin R. Fisher,Marc E. Lippman,D. Lawrence Wickerham,Norman Wolmark +9 more
TL;DR: The hypothesis of a preferential benefit from doxorubicin in patients with erbB-2-positive breast cancer is supported, with data supporting this hypothesis after a mean time of 13.5 years.
Journal ArticleDOI
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
Gerald Batist,Gopal Ramakrishnan,Chandra Sekhar Rao,Aruna Chandrasekharan,John Gutheil,Troy H. Guthrie,Pankaj Shah,Ali Khojasteh,Madhavan Krishnan Nair,Karen Hoelzer,Katherine Tkaczuk,Youn C. Park,Lily W. Lee +12 more
TL;DR: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.